A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

Manish A. Shah, Derek G. Power, Hedy L. Kindler, Kyle D. Holen, Margaret M. Kemeny, David H. Ilson, Laura Tang, Marinela Capanu, John J. Wright, David P. Kelsen

Research output: Contribution to journal › Article › peer-review

45 Scopus citations